Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 11:29AM EDT. Market open.
| Previous close | 29.26 |
| Open | 30.04 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 29.72 - 30.08 |
| 52-week range | 29.20 - 40.48 |
| Volume | |
| Avg. volume | 2,808,887 |
| Market cap | 193.118B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 15.37 |
| EPS (TTM) | 1.95 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 1.35 (4.61%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 37.86 |
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
- Thomson Reuters StreetEvents
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Q1 2024 Sarepta Therapeutics Inc Earnings Call
ZacksRoche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
© 2024 Yahoo. All rights reserved.